Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT05048797
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
454 Enrollment(s)
130 Study location(s)
INTERVENTIONAL (PHASE3)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
COMPLETED
NCT00117494
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
86 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Hyperlipidemia


HIV Infections
NOT_YET_RECRUITING
NCT07507500
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
8,100 Enrollment(s)
5 Study location(s)
INTERVENTIONAL (PHASE4)
Myocardial Infarction (MI)
RECRUITING
NCT06486883
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
200 Enrollment(s)
56 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Breast Cancer


Advanced Breast Carcinoma


Hormone Receptor Positive Breast Carcinoma
RECRUITING
NCT06145308
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
39 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Salivary Gland Carcinoma


Precision Therapy
TERMINATED
NCT05744375
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
2 Enrollment(s)
19 Study location(s)
INTERVENTIONAL (PHASE2)
Locally Advanced Breast Cancer


Metastatic Breast Cancer
RECRUITING
NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
4,200 Enrollment(s)
174 Study location(s)
INTERVENTIONAL (PHASE2)
Lymphoma, Non-Hodgkin


Multiple Myeloma


Advanced Solid Tumors
RECRUITING
NCT06740799
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
12 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE1)
Hepatic Impairment